Deal overview
| Target | BIOVERATIV INC |
|---|---|
| Bidder | SANOFI SA |
| Price | £90.00 Full version or £25.00 Light version |
| Publication Date | Jan 22, 2018 |
| Abstract | On 22 January 2018, the French healthcare and pharmaceuticals company Sanofi SA ("Sanofi") announced a recommended offer for the quoted US-based biopharmaceuticals group Bioverativ Inc ("Bioverativ"). The offer of US$ 105 per share in cash represented an equity value of approximately US$ 11.4 billion. The tender offer commenced on 7 February 2018 and expired on 7 March ... |
| Number of pages (Full version) | 9 |
| Number of pages (Light version) | 2 |
| Format | Adobe Acrobat (Download Acrobat Reader) |
| Free Sample | Click Here to Download |
Purchase this report
Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.
©2024 M&A Monitor Limited
